Open access

Genomic Characterization of ETV6::RUNX1‐Positive Childhood B‐ALL in a Chinese Cohort: Novel Fusion Partners, Co‐Occurring Mutations, and Risk‐Stratifying Biomarkers

Hua-Lei Luo Gui-Chi Zhou Qian Li Qiang Yao Yun-Sheng Chen Xue Tang Shi-Lin Liu Hui-Ying Ye Hui-Rong Mai Xiao-Ying Fu Ying Wang

Sep 2026 · Pediatric Blood & Cancer · Vol 73 · 0 citations · 28 references

Medicine

Abstract

ETV6::RUNX1 is the most common genetic abnormality in pediatric B‐cell acute lymphoblastic leukemia (ALL; ∼25%), yet the comprehensive genetic architecture and molecular predictors of intermediate‐risk (IR) stratification remain incompletely characterized.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Open access Sep 2026

Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3‐Rearranged Renal Cell Carcinoma: A Multicenter Real‐World Study

TFE3‐rearranged renal cell carcinoma (TFE3‐rRCC) is uncommon and encompasses biologically diverse tumors, while evidence to guide systemic treatment remains sparse. We examined clinical outcomes, treatment patterns, and molecular features in a multicenter real‐world cohort.

Shu-Xuan Zhu, Si-Qi Zhou, Xi Tian et al. · Cancer Medicine · 0 citations

Open access Aug 2026

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia

Nucleophosmin 1‐mutated (NPM1mt) acute myeloid leukemia (AML) is associated with a relatively favorable prognosis though long‐term outcomes remain suboptimal without clear predictors identified by therapy.

Aziz Farhat, Georgina El Hajjar, H. Kantarjian et al. · Cancer · 1 citation

Case report Open access Sep 2026

A Novel BRCA1 Pathogenic Variant in Tunisian Patient With High Grade Ovarian Cancer: Favorable Therapeutic Response to Olaparib

Ovarian cancer is one of the leading causes of death from gynecological cancer worldwide. Genetic mutations in genes involved in key cellular functions such as BRCA1/2 play a central role in tumorigenesis and have major implications for targeted therapeutic strategies, especially the use of poly (ADP‐ribose) polymerase...

N. Ammous-Boukhris, Rania Abdelmaksoud-Dammak, Ameni Feki et al. · Cancer Reports · 0 citations

Open access Sep 2026

DDX41 mutations establish a separate entity in acute myeloid leukemia with distinct survival outcomes

Recurrent germline variants in DDX41 represent the most common inherited predisposition to adult myeloid neoplasms, occurring in approximately 3% – 5% of patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). 1,2 Clinically, patients with DDX41 ‐ mutated AML are typically older at diagnosis, pred...

Carolin Seeling, Maral Saadati, D. Späth et al. · HemaSphere · 0 citations

Open access Aug 2026

Clinical Benefit of Pembrolizumab in Lynch Syndrome‐Associated Advanced Ovarian Cancer With Germline MSH6 Variant: A Case Report

This case highlights the importance of genetic evaluation during treatment in young patients with advanced ovarian cancer. Lynch syndrome caused by a germline MSH6 pathogenic variant was diagnosed during first‐line maintenance therapy, and pembrolizumab achieved a durable response in recurrent disease.

Tomomi Yokozawa, Sayako Nakagawa, Yukio Suzuki et al. · Clinical Case Reports · 0 citations

Open access Aug 2026

Does disease ontogeny matter more than JAK2 mutation status in acute myeloid leukemia?

We read with great interest the study by Albliwi et al. 1 evaluating cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia (AML) and their clinical significance. The authors are to be congratulated for assembling a large cohort and providing valuable insights into the heterogeneous biology of these...

Niveditha Suresh Babu, K. S. Sridevi Sangeetha · Cancer · 0 citations